A robust knowledge of how to reduce breast density could play a key role in breast cancer
prevention in premenopausal women, but viable preventative targets to reduce breast
density-associated breast cancer risk are yet to be developed. The investigators propose to
investigate the effect of RANKL inhibition with denosumab on breast tissue markers in
high-risk premenopausal women with dense breasts. Study findings could provide robust
evidence to move forward with a clinical trial targeting RANKL inhibition in premenopausal
breast cancer prevention.